Review of IUCD Complications: Lessons from CAT. Dr FG Mhlanga CAT Meeting 24 September 2016

Similar documents
Instruction for the patient

2

Application for inclusion of levonorgestrel - releasing IUD for contraception in the WHO Model List of Essential Medicines

LONG-ACTING REVERSIBLE CONTRACEPTION. Summary Tables

Simplifying Vide Contraception. University of Utah Department of Ob/Gyn Post Grad Course February 13, 2017 David Turok

BLEEDING PATTERNS AND CONTRACEPTIVE DISCONTINUATION FG MHLANGA MTN ANNUAL MEETING 20 MARCH 2018

The Doctor Is In. Brent N Davidson MD Vice Chair Women s Health Henry Ford Health System Medical Director Family Planning MDCH

What s New in Adolescent Contraception?

Unintended Pregnancy is Common LEARNING OBJECTIVES. Distribution Of Contraception Use By Women In The Us. Unintended Pregnancy And Contraceptive Use

FDA-Approved Patient Labeling Patient Information Mirena (mur-ā-nah) (levonorgestrel-releasing intrauterine system)

Emergency Contraception THE FACTS

LEARNING OBJECTIVES. Beyond the Pill: Long Acting Contraception. Distribution Of Contraception Use By Women In The Us. Unintended Pregnancy is Common

Contraception Choices: An Evidence Based Approach Case Study Approach. Susan Hellier PhD, DNP, FNP-BC, CNE

2

EXPERIENCES WITH BROADENING THE CONTRACEPTIVE MIX AT THE CAPRISA ETHEKWINI CRS

Family Planning UNMET NEED. The Nurse Mildred Radio Talk Shows

1. Ortiz, M. E et al. Mechanisms of action of intrauterine devices. Obstet & Gynl Survey 1996; 51(12), 42S-51S.

Wendy Shen, MD, PhD Refresher Course for the Family Physician April 5, 2018 Coralville, Iowa

Reproductive health research at WHO

levonorgestrel 13.5mg intrauterine delivery system (Jaydess ) SMC No. (1036/15) Bayer

Information for Informed Consent for Insertion of a Mirena IUD

Management of Emergency Contraception (EC)

Linda Gregg NP, Janet Isabell NP, Sue Montei NP Clinical Reviewers Reproductive Health Unit

International Journal of Research in Pharmaceutical and Nano Sciences Journal homepage:

Acute Salpingitis. Fallopian Tubes. Uterus

Welcome to Mirena. The Mirena Handbook: A Personal Guide to Your New Mirena. mirena.com. Mirena is the #1 prescribed IUD * in the U.S.

Levosert levonorgestrel 20mcg/24hour intrauterine device

Contraception. Objectives. Unintended Pregnancy. Unintended Pregnancy in the US. What s the Impact? 10/7/2014

VCHIP LARC Needs Assessment Survey

The number of women using long-acting reversible

Table I. Examples of Hormone and Tapering Regimens

Extended use of intrauterine devices: How long can we go?

Product Information. Confidence that lasts

Postpartum LARC. (Long Acting Reversible Contraception) NURSING EDUCATION

Contraception: I. Non-Hormonal Methods

ClincialTrials.gov Identifier: sanofi-aventis. Sponsor/company:

Expanding Access to Birth Control: Will Women Get the Care They Need?

WHAT ARE CONTRACEPTIVES?

Contraceptive Updates and Recommendations

Contraceptive Updates and Recommendations

ACCESS LARC INCREASING ACCESS TO IMMEDIATE POSTPARTUM LONG-ACTING REVERSIBLE CONTRACEPTION

BRIEF REPORTS. Providing Long-Acting Reversible Contraception in an Academic Family Medicine Center Jennifer Amico, MD, MPH; Justine Wu, MD, MPH

Immediate Postpartum Long-Term Reversible Contraception (LARC) Bethany Berry, CNM, MSN and Alyssa Givens, MSN, RN

Update on the Evidence for Contraceptive Options and HIV Outcomes (ECHO) Trial

Carl Gustaf Nilsson, M.D. t:j: Hannu Allonen, M.D. Juan Diaz, M.D.II Tapani Luukkainen, M.D., Ph.D.t

A systematic review of some of the side effects of copper T380 intrauterine contraceptive device

Key words: Contraception, Copper T380A, Discontinuation.

LARC: Disclosures. Long Acting Reversible Contraception. Objectives 10/23/2013. I have no relevant financial disclosures

The Evidence for Contraceptive Options and HIV Outcomes (ECHO) Trial

Contraception and gynecological pathologies

Contraception for Adolescents: What s New?

Hormonal contraception and HIV risk

Multipurpose Intravaginal Ring: Tenofovir / Levonorgestrel

The following lesson on contraception (birth control) is not intended to infer that you will be sexually active as a teen. This is information that

Time Topic Speaker Abbreviation

Notes to Teacher continued Contraceptive Considerations

Contraception: Common Problems Faced in Office Practice. Jane S. Sillman, MD Brigham and Women s Hospital

Family Planning د. نجمه محمود كلية الطب جامعة بغداد فرع النسائية والتوليد

Package leaflet: Information for the user. Levonorgestrel 1.5 mg Tablet. levonorgestrel

A Comparative Study between the Side Effects of Copper Intrauterine Device in Women with Non-scarred and Scarred Uterus

Medical Eligibility for Contraception Use

Clinical Study Synopsis

Prescriber and Pharmacy Guide for the Tracleer REMS Program

the IUD the IUD the IUD the IUD the IUD the IUD the IUD the IUD the IUD the IUD the IUD the IUD the IUD your guide to

Example Clinical Guideline for Immediate Postpartum LARC Insertion

Chapter 7 Infertility, Contraception, and Abortion

ORIGINAL ARTICLE Fertility control

1. Ng M et a l. Global, regional, and national prevalence of overweight and obesity in children and adults during : A systematic analysis

Examining Long-Acting Reversible Contraceptive Methods

Maximizing LARC Availability: Bringing the Lessons of the CHOICE Project to Your Community

Improving private sector

Dr. Russo reports no financial relationships relevant to this article. Dr Creinin is a senior clinical advisor for Medicines360.

Final Report: Qualitative Interviews with Mirena Users and their Partners in Kenya

Coding for the Contraceptive Implant and IUDs

Trends in use of and complications from intrauterine contraceptive devices and tubal ligation or occlusion

Can an iud cause back pain

Example CLINICAL GUIDELINES for Postpartum IUD insertion

Contraception Update: what s new in 2016? Felicity Young MA BSc (Hons) RMN RGN RM NDFSRH A08 Consultant Nurse for Sexual and Reproductive Healthcare

Contraceptives. Kim Dawson October 2010

INTRAUTERINE DEVICES AND INFECTIONS. Tips for Evaluation and Management

Heavy Menstrual Bleeding. Mr Nick Nicholas MD FRCOG Grad Dip Law. Consultant Gynaecologist

An Illustrative Communication Strategy for Contraceptive Implants

An Overview of Long Acting Reversible Contraception Methods

Ardhanu Kusumanto Oktober Contraception methods for gyne cancer survivors

Trends in Modern Contraceptive Prevalence Rate among Currently Married Women in Uganda:

The use of long-acting reversible contraceptive

Intrauterine Devices (IUDs): Access for Women in the U.S.

LARC IN THE OFFICE BASE SETTING. Regina Lewis, DO Associate Professor of Family Medicine OSU Family Medicine

CODING GUIDELINES FOR CONTRACEPTIVES. Effective June 1, 2017 Version 1.40

CONFERENCE SCHEDULE. Demonstrate correct hand skills necessary for placement of the copper IUD and each of the three levonorgestrel IUDs.

One-day Essentials Contraception. Dr Paula Briggs, General Practitioner, Clinical Lead Community Sexual Health, Sefton and West Lancashire

Zurich Open Repository and Archive

Adolescent pregnancies have declined

Contraception. IUC s, Sterilization

Adolescent Hot Topics: Contraception

4. Timing of post-abortion contraception

MIDWIVES IN CONTRACEPTION AND FERTILITY PLANNING 15 TH ANNUAL SOMSA CONGRESS BLOEMFONTEIN AUGUST 2018

CHAPTER 4 REPRODUCTIVE HEALTH POINTS TO REMEMBER

Fitting of an Intrauterine Device (IUD)

Transcription:

Review of IUCD Complications: Lessons from CAT Dr FG Mhlanga CAT Meeting 24 September 2016

INTRODUCTION The intrauterine device (IUD) is a reliable long term reversible, cost-effective,easy to use and low maintenance method of contraception. Contains either copper (Cu T380A) or Levonorgestrel (LNG 20 or LNG 14) Has very few contraindications and generally advantages outweigh risks Side effects from the IUD are minimal and complications are rare.

Introduction Can be inserted at any point during a woman s menstrual cycle (if pregnancy excluded) or immediately postpartum and, once inserted, provides immediate efficacy May be used for emergency contraception. Data on the use of the copper IUD in the developing world is limited It is so cost effective: why is the use of IUCD so limited?

Barriers To IUCD Three key barriers to IUCD uptake have been identified at MTN sites: 1. Bias: provider, community, and participant 2. Lack of IUD insertion training especially among nurses 3. Lack of IUCDs on site

The ASPIRE Experience We trained Nurses & Physicians IUCD insertion IUCD were made available on site Of 2629 women enrolled in ASPIRE, 595 (23%) had an IUD inserted during study participation. Of these, 403 were inserted at MTN sites Questions: 1. Was IUD insertion equally well tolerated when done by nurses vs physicians? 2. Were expulsion rates similar for nurses and physicians? 3. How do our rates of complications compare with published data?

The ASPIRE Experience- methods Data abstracted from study charts: type of provider performing the IUD insertion related complications side effects Descriptive statistics were used to summarize key factors The proportion of women experiencing select complication/side effects were compared across provider types using the Chi-squared test.

Characteristics of 556 Women Getting IUCDs in ASPIRE

Complications of IUD Insertion *All others includes those insertions by staff at health facility, staff at private health facility or unknown.**uterine pain, backache, anaemia, partner feeling the IUD at intercourse, urinary tract infection, nausea and vomiting. P-values generated using Chi-squared test comparing differences across the three groups for the selected complications/side-effect

Key Findings The majority of women had IUDs inserted by study staff (trained nurses or physicians) Overall, the most common sides effects were irregular bleeding (44%) and postinsertion pelvic pain (23%). No reports of uterine perforation were observed IUD expulsions occurred more often than observed in US studies.

A 3-year multicentre randomized controlled trial of etonogestrel- and levonorgestrel-releasing contraceptive implants, with non-randomized matched copper-iuds Large WHO study published in 2015 reported results from Brazil, Chile, Dominican Republic, Hungary, Thailand, Turkey and Zimbabwe. Study Population: 2982 women ENG-implant n=1003 (PP n=995) LNG-implant n= 1005 (PP n=997) IUD groups n=974 (PP n=971) Follow-ups: 2 weeks, 3 and 6 months, and semi-annually thereafter for 3 years or until pregnancy, removal or expulsion of the implant/iud occurred. Outcomes: pregnancy rates, bleeding, discontinuation rates and IUD expulsions Bahamondes L et al. Human Reproduction 2015 Nov;30(11):2527-38

WHO Study Method Continuation Rates ENG: 2.5 years 69.8 (95% CI 66.8-72.6) 3.0 years 12.1 (95% CI 5.2-22.0) LNG: 2.5 years 71.8 per 100 W-Y (68.8-74.5) 3 years 52.0 per 100 W-Y (95% CI 41.8-61.2) Top reason for discontinuation? Bleeding disturbances! More common in the ENG vs LNG group 16.7 vs 12.5, P =0.019

WHO Study IUD Results IUD 3-year expulsion rate; 17.8 per 100 W-Y (95% CI 14.5-21.9) Discontinuation rate for bleeding disturbances was 8.5 (95% CI 6.7-10.9) lower than for implants. Bleeding complications irregularities more frequent among implant users (P < 0.0001) Heavy bleeding and lower abdominal pain more frequent among IUD vs implant users (P < 0.0001).

Conclusions Complications similar between physician and nurses: PID, bleeding irregularities missing strings Complications different: pelvic pain expulsions Additional investigation is required to understand the contributors to IUD expulsion and pelvic pain in this setting in order to reduce its frequency in the future.

Acknowledgements We are grateful to: Study participants The research communities CABs Jen Balkus The Protocol Management team and MTN Leadership